)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
TScan Therapeutics
TScan Therapeutics (TCRX) investor relations material
TScan Therapeutics TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen 46th Annual Health Care Conference summary4 Mar, 2026
Program overview and clinical progress
Lead asset targets residual disease in heme malignancies post-allogeneic transplant, aiming to prevent relapse.
Phase I data showed a hazard ratio of 0.5 for relapse-free survival, with long-term persistence of engineered T cells.
FDA agreement reached on pivotal trial design, with study launch planned for Q2 and top-line readout expected by end of 2028.
Commercial-ready manufacturing process reduces production time from 17 to 12 days and is more efficient.
Cohort C with 10+ patients using the new process is fully enrolled, with data to be shared in Q2.
Market opportunity and expansion plans
Initial addressable market for TSC-101 is 2,100 patients/year in the U.S., with a peak revenue estimate of over $1.4 billion.
Global addressable market for TSC-101 is about 7,500 patients/year, expanding to 15,000/year with additional HLA-targeted products.
Two new INDs cleared for HLA expansion, with further products in late-stage discovery.
Potential to address up to 20,000 patients/year with future oncology and non-oncology indications.
Product pricing expected to align with other cell therapies, estimated at $675,000 per treatment.
Clinical data and safety profile
Phase I study included 23 treatment and 19 control patients, with balanced risk profiles.
Product demonstrated a strong safety profile, with only mild and manageable adverse events.
Most patients converted to MRD negative after first infusion, with improved donor chimerism in the treatment arm.
Chimerism at two months is a strong predictor of long-term outcomes.
Engineered T cells persist long-term in all tested patients.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next TScan Therapeutics earnings date
Q1 20265 May, 2026
TScan Therapeutics
Next TScan Therapeutics earnings date
Q1 20265 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T cell receptor-engineered T cell (TCR-T) therapies to treat cancer. The company's lead candidates, TSC-100 and TSC-101, target hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation. Additionally, TScan is advancing a pipeline of multiplexed TCR-T therapies for solid tumors, supported by its proprietary ImmunoBank, which houses a diverse collection of therapeutic TCRs. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage